Cancer Research Prevention Award Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linardakis, E.
Right arrow Articles by Vile, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linardakis, E.
Right arrow Articles by Vile, R.
[Cancer Research 62, 5495-5504, October 1, 2002]
© 2002 American Association for Cancer Research

Immunology

Enhancing the Efficacy of a Weak Allogeneic Melanoma Vaccine by Viral Fusogenic Membrane Glycoprotein-mediated Tumor Cell-Tumor Cell Fusion1

Emmanouela Linardakis, Andrew Bateman, Vy Phan, Atique Ahmed, Michael Gough, Kenneth Olivier, Rick Kennedy, Fiona Errington, Kevin J. Harrington, Alan Melcher and Richard Vile2

Molecular Medicine Program [E. L., A. B., V. P., A. A., M. G., K. O., R. V.] and Department of Immunology [R. K.], Mayo Clinic, Rochester, Minnesota 55905; Imperial Cancer Research Fund Oncology Unit, St. James Hospital, Leeds, United Kingdom [F. E., A. M.]; and Chester Beatty Laboratories, Fulham Road, London, United Kingdom [K. J. H.]

We have investigated how to make K1735 cells, a poor allogeneic melanoma vaccine, more effective for protection against B16 in vivo. To promote antigen release in an immunologically effective manner, tumor cells were transfected with a viral fusogenic membrane glycoprotein (vesicular stomatitis virus G glycoprotein), which kills cells through the formation, and degeneration, of large multinucleated syncytia. Vaccines consisting of a 1:1 mix of fusing allogeneic and autologous cells led to dramatic increases in survival of mice in both prophylactic and therapy models, dependent upon T cells, the mechanism of tumor-tumor cell fusion, and the nature of the fusion partner. Syncytia activate macrophages and fusogenic membrane glycoprotein-mediated cell killing very efficiently promotes cross-priming of immature dendritic cells with a model tumor antigen. Our data suggest that the unique manner in which syncytia develop and die provides a highly effective pathway for tumor antigen release and presentation to the immune system and offers a novel mechanism by which cancer cell vaccines may be prepared for clinical use.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
R. J. Prestwich, E. J. Ilett, F. Errington, R. M. Diaz, L. P. Steele, T. Kottke, J. Thompson, F. Galivo, K. J. Harrington, H. S. Pandha, et al.
Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication
Clin. Cancer Res., July 1, 2009; 15(13): 4374 - 4381.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. W. Brown, K. B. Stephenson, S. Hanson, M. Kucharczyk, R. Duncan, J. C. Bell, and B. D. Lichty
The p14 FAST Protein of Reptilian Reovirus Increases Vesicular Stomatitis Virus Neuropathogenesis
J. Virol., January 15, 2009; 83(2): 552 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Kottke, J. Thompson, R. M. Diaz, J. Pulido, C. Willmon, M. Coffey, P. Selby, A. Melcher, K. Harrington, and R. G. Vile
Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2
Clin. Cancer Res., January 15, 2009; 15(2): 561 - 569.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R. M. Diaz, J. Thompson, P. Selby, J. de Bono, A. Melcher, et al.
Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
Clin. Cancer Res., January 1, 2008; 14(1): 259 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Kottke, L. Sanchez-Perez, R. M. Diaz, J. Thompson, H. Chong, K. Harrington, S. K. Calderwood, J. Pulido, N. Georgopoulos, P. Selby, et al.
Induction of hsp70-Mediated Th17 Autoimmunity Can Be Exploited as Immunotherapy for Metastatic Prostate Cancer
Cancer Res., December 15, 2007; 67(24): 11970 - 11979.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Hoffmann, W. Bayer, T. Grunwald, and O. Wildner
Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer
Mol. Cancer Ther., July 1, 2007; 6(7): 1942 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. M. Diaz, F. Galivo, T. Kottke, P. Wongthida, J. Qiao, J. Thompson, M. Valdes, G. Barber, and R. G. Vile
Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus
Cancer Res., March 15, 2007; 67(6): 2840 - 2848.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
U. Thanarajasingam, L. Sanz, R. Diaz, J. Qiao, L. Sanchez-Perez, T. Kottke, J. Thompson, J. Chester, and R. G. Vile
Delivery of CCL21 to Metastatic Disease Improves the Efficacy of Adoptive T-Cell Therapy
Cancer Res., January 1, 2007; 67(1): 300 - 308.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Sanchez-Perez, T. Kottke, G. A. Daniels, R. M. Diaz, J. Thompson, J. Pulido, A. Melcher, and R. G. Vile
Killing of Normal Melanocytes, Combined with Heat Shock Protein 70 and CD40L Expression, Cures Large Established Melanomas
J. Immunol., September 15, 2006; 177(6): 4168 - 4177.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Errington, A. Bateman, T. Kottke, J. Thompson, K. Harrington, A. Merrick, P. Hatfield, P. Selby, R. Vile, and A. Melcher
Allogeneic Tumor Cells Expressing Fusogenic Membrane Glycoproteins as a Platform for Clinical Cancer Immunotherapy
Clin. Cancer Res., February 15, 2006; 12(4): 1333 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Sanchez-Perez, T. Kottke, R. M. Diaz, A. Ahmed, J. Thompson, H. Chong, A. Melcher, S. Holmen, G. Daniels, and R. G. Vile
Potent Selection of Antigen Loss Variants of B16 Melanoma following Inflammatory Killing of Melanocytes In vivo
Cancer Res., March 1, 2005; 65(5): 2009 - 2017.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.